PDCD1 and non-small cell lung carcinoma: Among these, immune checkpoint inhibitors (ICIs), specifically programmed death-1 (PD-1) inhibitors, have demonstrated significant success in treating advanced NSCLC (Yang et al., 2020; Flores et al., 2021).